ArticleEvidence-based complementary and alternative medicine : eCAM2011
Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission.
Article in Evidence-based complementary and alternative medicine : eCAM, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Medicinal Mushroom Supplements in Cancer: A Systematic Review of Clinical Studies.Current oncology reports · 2023Pooled it
- Trial
- Trial
- Immunomodulatory effects of the Agaricus blazei Murrill-based mushroom extract AndoSan in patients with multiple myeloma undergoing high dose chemotherapy and autologous stem cell transplantation: a randomized, double blinded clinical study.BioMed research international · 2015Trial
- The Inclusion of Dietary and Medicinal Mushrooms into Translational Oncology: Pros and Cons at the Molecular Level.International journal of molecular sciences · 2026Review
- Immunomodulatory Effects of Multivitamin Complexes ContainingBiomedicines · 2025Article
- Medicinal Mushrooms in Metastatic Breast Cancer: What Is Their Therapeutic Potential as Adjuvant in Clinical Settings?Current issues in molecular biology · 2024Review
- Agaritine derived fromFujita medical journal · 2023Article
- Mushroom Polysaccharide-Assisted Anticarcinogenic Mycotherapy: Reviewing Its Clinical Trials.Molecules (Basel, Switzerland) · 2022Review
- Fungal Mushrooms: A Natural Compound With Therapeutic Applications.Frontiers in pharmacology · 2022Review
- Mycopharmaceuticals and Nutraceuticals: Promising Agents to Improve Human Well-Being and Life Quality.Journal of fungi (Basel, Switzerland) · 2021Review
- A Narrative Review of the Role of Diet and Lifestyle Factors in the Development and Prevention of Endometrial Cancer.Cancers · 2021Review
- Medicinal Mushrooms: Bioactive Compounds, Use, and Clinical Trials.International journal of molecular sciences · 2021Review
- Novel Medicinal Mushroom Blend as a Promising Supplement in Integrative Oncology: A Multi-Tiered Study using 4T1 Triple-Negative Mouse Breast Cancer Model.International journal of molecular sciences · 2020Article
- Shaping the Innate Immune Response by Dietary Glucans: Any Role in the Control of Cancer?Cancers · 2020Review
- Feed additive blends fed to nursery pigs challenged with Salmonella.Journal of animal science · 2020Article
- Article
- Immune Modulation From Five Major Mushrooms: Application to Integrative Oncology.Integrative medicine (Encinitas, Calif.) · 2014Review
- The cancer preventive effects of edible mushrooms.Anti-cancer agents in medicinal chemistry · 2012Review
- Agaricus subrufescens: A review.Saudi journal of biological sciences · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although many cancer patients use complementary and alternative medicine, including Agaricus blazei Murill (ABM), safety is not yet well understood. Cancer survivors took 1.8, 3.6, or 5.4 g ABM granulated powder (Kyowa Wellness Co., Ltd., Tokyo, Japan) per day orally for 6 months. Adverse events were defined by subjective/objective symptoms and laboratory data according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (NCI-CTCAE v3.0). Seventy-eight patients were assessed for safety of ABM (30/24/24 subjects at 1/2/3 packs per day, resp.). Adverse events were observed in 9 patients (12%). Most were digestive in nature such as nausea and diarrhea, and one patient developed a liver dysfunction-related food allergy, drug lymphocyte product. However, none of these adverse events occurred in a dose-dependent manner. This study shows that ABM does not cause problems in most patients within laboratory parameters at the dosages tested over 6 months. This trial supports previous evidence that the ABM product is generally safe, excluding possible allergic reaction.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.